David Blaine Ridley

David Blaine Ridley

Professor of the Practice of Economics

External Address: 
100 Fuqua Drive, Durham, NC 27708-0120
Internal Office Address: 
Duke Box 90120, 100 Fuqua Drive, Durham, NC 27708-0120
(919) 660-3784

David Ridley is the Faculty Director of Health Sector Management at Duke University’s Fuqua School of Business. In his research, he examines innovation and pricing in health care. David was the lead author of the paper proposing the priority review voucher program which became law in 2007 and created a market of more than a billion dollars for drug development for neglected diseases. He was the principal investigator on a grant from the Bill & Melinda Gates Foundation for 2018 to 2020. He teaches courses on health care economics, policy, and strategy to graduate students. He received a PhD in economics from Duke University.


  • Ph.D., Duke University 2001
  • M.A., Duke University 1995
  • B.A., University of Missouri, Columbia 1993

Ridley, D. B. “Herding versus Hotelling: Market entry with costly information.” Journal of Economics and Management Strategy 17, no. 3 (September 1, 2008): 607–31. https://doi.org/10.1111/j.1530-9134.2008.00188.x. Full Text

Ridley, David B. “International price comparisons for novel and follow-on drugs.Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 10, no. 6 (November 2007): 510–11. https://doi.org/10.1111/j.1524-4733.2007.00238.x. Full Text

Kyle, Margaret K., and David B. Ridley. “Would greater transparency and uniformity of health care prices benefit poor patients?Health Affairs (Project Hope) 26, no. 5 (September 2007): 1384–91. https://doi.org/10.1377/hlthaff.26.5.1384. Full Text

Grabowski, H. G., D. B. Ridley, and K. A. Schulman. “Entry and competition in generic biologics.” Managerial and Decision Economics 28, no. 4–5 (June 1, 2007): 439–51. https://doi.org/10.1002/mde.1352. Full Text Open Access Copy

Ridley, David B., Henry G. Grabowski, and Jeffrey L. Moe. “Developing drugs for developing countries.Health Affairs (Project Hope) 25, no. 2 (March 2006): 313–24. https://doi.org/10.1377/hlthaff.25.2.313. Full Text Open Access Copy

Ridley, David B., Judith M. Kramer, Hugh H. Tilson, Henry G. Grabowski, and Kevin A. Schulman. “Spending on postapproval drug safety.Health Aff (Millwood) 25, no. 2 (March 2006): 429–36. https://doi.org/10.1377/hlthaff.25.2.429. Full Text Open Access Copy

Ridley, D. B., and J. M. Kramer. “Postapproval drug safety: The authors respond [8].” Health Affairs 25, no. 4 (January 1, 2006): 1187–88. https://doi.org/10.1377/hlthaff.25.4.1184-a. Full Text

Ridley, David B., and Kirsten J. Axelsen. “Impact of Medicaid preferred drug lists on therapeutic adherence.Pharmacoeconomics 24 Suppl 3 (January 2006): 65–78. https://doi.org/10.2165/00019053-200624003-00006. Full Text

Ridley, David B., and Judith M. Kramer. “Postapproval drug safety: The authors respond.” Health Affairs 25, no. 4 (2006): 1187–88. https://doi.org/10.1377/hlthaff.25.4.1187. Full Text